WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

Search

Hims & Hers Health Inc

Geschlossen

BrancheKonsumgüter defensiv

27.92 -10.34

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

27.74

Max

29.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

-50M

26M

Verkäufe

80M

481M

KGV

Branchendurchschnitt

54.722

44.466

EPS

0.227

Gewinnspanne

5.409

Angestellte

1,637

EBITDA

-8.2M

19M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+49.76% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

5. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-4.7B

6.5B

Vorheriger Eröffnungskurs

38.26

Vorheriger Schlusskurs

27.92

Nachrichtenstimmung

By Acuity

50%

50%

63 / 152 Ranking in Consumer defensive

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Hims & Hers Health Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Apr. 2025, 23:15 UTC

Wichtige Markttreiber

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25. Feb. 2025, 15:33 UTC

Wichtige Markttreiber

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18. Nov. 2024, 19:07 UTC

Wichtige Markttreiber

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14. Okt. 2024, 15:02 UTC

Wichtige Markttreiber

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3. Okt. 2024, 11:28 UTC

Wichtige Markttreiber

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

2. Apr. 2025, 16:53 UTC

Top News

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19. März 2025, 15:54 UTC

Top News

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21. Feb. 2025, 23:20 UTC

Ergebnisse

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10. Feb. 2025, 12:00 UTC

Top News

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19. Dez. 2024, 17:16 UTC

Top News

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19. Dez. 2024, 15:14 UTC

Top News

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19. Dez. 2024, 15:02 UTC

Top News

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16. Dez. 2024, 13:47 UTC

Top News

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16. Dez. 2024, 07:00 UTC

Top News

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3. Okt. 2024, 14:45 UTC

Top News

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3. Okt. 2024, 13:12 UTC

Top News

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3. Okt. 2024, 11:45 UTC

Top News

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3. Okt. 2024, 10:14 UTC

Top News

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2. Aug. 2024, 17:52 UTC

Akquisitionen, Fusionen, Übernahmen

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26. Juni 2024, 11:00 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24. Mai 2024, 20:37 UTC

Ergebnisse

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Peer-Vergleich

Kursveränderung

Hims & Hers Health Inc Prognose

Kursziel

By TipRanks

49.76% Vorteil

12-Monats-Prognose

Durchschnitt 46.5 USD  49.76%

Hoch 85 USD

Tief 21 USD

Basierend auf 13 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Hims & Hers Health Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

13 ratings

5

Buy

6

Halten

2

Sell

Technischer Score

By Trading Central

31.0237 / 31.88Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Weak Bullish Evidence

Stimmung

By Acuity

63 / 152 Ranking in Konsumgüter defensiv

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.